Cancer Prevention Research 2, 525, June 1, 2009. Published Online First May 26, 2009;
doi: 10.1158/1940-6207.CAPR-08-0223
© 2009 American Association for Cancer Research
Development of Dietary Phytochemical Chemopreventive Agents: Biomarkers and Choice of Dose for Early Clinical Trials
Edwina N. Scott,
Andreas J. Gescher,
William P. Steward and
Karen Brown
Authors' Affiliation: Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom
Requests for reprints: Karen Brown, Chemoprevention Group, Department of Cancer Studies and Molecular Medicine, Level 5, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, United Kingdom. Phone: 44-116-223-1851; Fax: 44-116-258-5942; E-mail: kb20{at}le.ac.uk.
In view of safety concerns surrounding the use of pharmaceuticals such as nonsteroidal anti-inflammatory drugs and tamoxifen as cancer chemopreventive agents, potentially innocuous phytochemicals derived from the diet are considered attractive alternatives. However, results from cancer chemoprevention trials of dietary agents have been disappointing to date, as promising activities observed in rodent models and cells in vitro have not translated into clinical success. This may be partly due to the development process for these agents, which is complex for a number of reasons; the definitive end point, inhibition of carcinogenesis, requires large numbers of individuals followed-up over many years. Furthermore, whereas biomarkers are frequently used as surrogate efficacy end points to expedite the process, biomarker assessment and validation has proven difficult because dietary agents exert multiple actions with an unknown hierarchy of biological importance. These factors have made determining the dose for clinical investigation extremely challenging, and at present, there are no defined strategies for rationally identifying the most appropriate doses. In this commentary, the complexities involved in the development of dietary chemoprevention agents are discussed, and a tentative route towards selection of the optimal clinical dose is proposed. The approach highlights the need to conduct long-term preclinical studies with realistic concentrations that are achievable in human tissues and the importance of efficacy biomarkers that are intrinsically linked to the key mechanisms of action. A more logical design of studies should increase the likelihood that the encouraging preclinical results observed for many phytochemicals translate into tangible clinical benefit.
Key Words: chemoprevention • clinical • dietary • doses
Copyright © 2009 by the American Association for Cancer Research.
